Table 1 Demographic characteristics.
Characteristic | Overall (N = 168) | Control group (N = 69) | Treatment delay group (N = 99) | p-value |
|---|---|---|---|---|
Length of delay | 44 (37) | NA (NA) | 44 (37) | |
Age | 84 (8) | 85 (7) | 84 (8) | 0.3 |
Gender | 0.6 | |||
F | 112 (67%) | 48 (70%) | 64 (65%) | |
M | 56 (33%) | 21 (30%) | 35 (35%) | |
Race | 0.4 | |||
Asian | 7 (4.2%) | 1 (1.4%) | 6 (6.0%) | |
Black | 4 (2.4%) | 2 (2.9%) | 2 (2.0%) | |
Hispanic | 1 (0.6%) | 0 (0%) | 1 (1.0%) | |
White | 153 (91%) | 66 (96%) | 87 (88%) | |
Unknown | 3 (1.8%) | 0 (0%) | 3 (3.0%) | |
Visit 1 injection | 0.3 | |||
Bevacizumab | 82 (49%) | 29 (42%) | 53 (54%) | |
Aflibercept | 69 (41%) | 32 (46%) | 37 (37%) | |
Ranibizumab | 17 (10%) | 8 (12%) | 9 (9.1%) | |
Visit 1 injection interval in weeks | 8.65 (2.91) | 9.20 (3.23) | 8.27 (2.61) | 0.05 |
Number of days of follow-up since visit 1 | 261 (55) | 258 (37) | 263 (64) | 0.6 |
Days between visit 1 to visit 2 | 91 (47) | 66 (29) | 109 (49) | < 0.001 |
Days of follow-up from visit 2 to visit 3 | 170 (46) | 192 (43) | 155 (43) | < 0.001 |
Pre-COVID VA logMAR | ||||
Mean (SD) | 0.531 (0.482) | 0.585 (0.550) | 0.493 (0.428) | 0.25 |
Pre-COVID OCT CMT | ||||
Mean (SD) | 297 (109) | 301 (131) | 294 (90.4) | 0.69 |
Injection interval at v3 | ||||
Mean (SD) | 8.98 (2.99) | 9.49 (3.19) | 8.62 (2.80) | 0.073 |
Inter-group comparison of v1 to v3 injection interval change | ||||
Mean (SD) | 0.303 (1.43) | 0.235 (1.07) | 0.351 (1.65) | 0.59 |
Years receiving treatment at v1 | ||||
Mean (SD) | 3.74 (2.27) | 3.66 (1.66) | 3.79 (2.62) | 0.69 |
Days receiving treatment at v1 | ||||
Mean (SD) | 1360 (829) | 1340 (605) | 1380 (958) | 0.69 |
2 or more years of treatment at v1 | ||||
No | 42 (25.0%) | 12 (17.4%) | 30 (30.3%) | 0.085 |
Yes | 126 (75.0%) | 57 (82.6%) | 69 (69.7%) | |
